Macrosalb

Macrosalb, the active ingredient in Macrosalb, is a radiopharmaceutical presented as a kit for reconstitution for intravenous use. It is employed to evaluate pulmonary blood flow during lung perfusion imaging and ventilation‑perfusion (V/Q) scans, primarily in adult patients suspected of pulmonary embolism or other perfusion abnormalities.

GNH USA supplies Macrosalb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic centres and procurement teams worldwide, ensuring regulatory‑approved quality and reliable delivery through established cold‑chain logistics where required and comprehensive after‑sales support.

Macrosalb is used in nuclear medicine to assess pulmonary blood flow and ventilation‑perfusion status. - Lung perfusion imaging: Enables visualization of regional pulmonary blood flow to identify perfusion defects. - Ventilation‑perfusion (V/Q) scan: Provides combined functional assessment of ventilation and perfusion for diagnosing pulmonary embolism. - Pulmonary embolism evaluation: Assists in confirming or ruling out embolic obstruction in the pulmonary arteries.

Adverse reactions to Macrosalb are generally related to the radiopharmaceutical nature of the preparation and the intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the site of intravenous administration. - Transient flushing: brief warmth or redness of the skin. - Nausea: mild, short‑lasting feeling of stomach upset. - Headache: mild to moderate headache occurring shortly after injection.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis requiring immediate medical intervention. - Pulmonary hypertension: sudden increase in pulmonary arterial pressure. - Embolic phenomena: rare lodging of particles causing perfusion defects beyond intended capillary distribution. - Radiation‑induced skin injury: localized erythema or ulceration at high exposure sites.

Precautions for Macrosalb focus on patient safety and proper handling of the radiopharmaceutical. - Pregnancy: use only if clearly needed after risk‑benefit assessment. - Breastfeeding: consider discontinuation of nursing or evaluate potential risks. - Renal impairment: monitor as altered clearance may affect distribution. - Allergy to albumin or technetium: avoid use in known hypersensitivity. - Concurrent radionuclide studies: schedule to prevent overlapping radiation exposure. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Interactions with other agents may influence imaging quality or particle distribution.

Major Interactions (Avoid): - Other radiopharmaceuticals: simultaneous use may cause image overlap and inaccurate interpretation. - Iodinated contrast agents: recent administration can alter pulmonary perfusion imaging results.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitroglycerin): may modify capillary blood flow and affect particle distribution. - Steroids: high doses can change capillary permeability, potentially influencing particle lodging. - Anticoagulants: may affect microvascular clotting, altering expected particle entrapment. - Beta‑blockers: may reduce cardiac output, influencing pulmonary perfusion patterns.